Inhibiteurs des histone-désacétylases : la régulation épigénétique sort de l’ombre

Bulletin du Cancer - Tập 97 - Trang 917-935 - 2010
N. Pécuchet1, T. Cluzeau2, C. Thibault1, N. Mounier2, S. Vignot1
1Groupe hospitalier Pitié-Salpêtrière, Service d’oncologie médicale, 75013 Paris, France
2Hôpital l’Archet, Service d’oncohématologie médicale, 06000 Nice, France

Tài liệu tham khảo

Baylin, 2000, DNA hypermethylation in tumorigenesis: epigenetics joins genetics, Trends Genet, 16, 168, 10.1016/S0168-9525(99)01971-X

Bird, 2002, DNA methylation patterns and epigenetic memory, Genes Dev, 16, 6, 10.1101/gad.947102

Feinberg, 2004, The history of cancer epigenetics, Nat Rev Cancer, 4, 143, 10.1038/nrc1279

Jenuwein, 2001, Translating the histone code, Science, 293, 1074, 10.1126/science.1063127

Jones, 2002, The fundamental role of epigenetic events in cancer, Nat Rev Genet, 3, 415, 10.1038/nrg816

Strahl, 2000, The language of covalent histone modifications, Nature, 403, 41, 10.1038/47412

Esteller, 2008, Epigenetics in Cancer, N Engl J Med, 358, 1148, 10.1056/NEJMra072067

Felsenfeld, 2003, Controlling the double helix, Nature, 421, 448, 10.1038/nature01411

Khorasanizadeh, 2004, The nucleosome: from genomic organization to genomic regulation, Cell, 116, 259, 10.1016/S0092-8674(04)00044-3

Johnstone, 2002, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, Nat Rev Drug Discov, 1, 287, 10.1038/nrd772

Van Lint, 1996, The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation, Gene Expr, 5, 245

Gray, 2004, Microarray profiling of effects of histone deacetylase inhibitors on gene expression in cancer cell lines, Int J Oncol, 24, 773

Ellis, 2008, Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors, Biochem Biophys Res Commun, 367, 656, 10.1016/j.bbrc.2007.12.157

Bolden, 2006, Anticancer activities of histone deacetylase inhibitors, Nat Rev Drug Discov, 9, 769, 10.1038/nrd2133

Dokmanovic, 2007, Histone deacetylase inhibitors: overview and perspectives, Mol Cancer Res, 5, 981, 10.1158/1541-7786.MCR-07-0324

Yang, 2008, Lysine acetylation: codified crosstalk with other posttranslational modifications, Mol Cell, 31, 449, 10.1016/j.molcel.2008.07.002

Spange, 2009, Acetylation of non-histone proteins modulates cellular signalling at multiple levels, Int J Biochem Cell Biol, 41, 185, 10.1016/j.biocel.2008.08.027

de Ruijter, 2003, Histone deacetylases (HDACs): characterization of the classical HDAC family, Biochem J, 370, 737, 10.1042/bj20021321

Yoshida, 1990, Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin, A. J Biol Chem, 265, 17174, 10.1016/S0021-9258(17)44885-X

Haigis, 2006, Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction, Genes Dev, 20, 2913, 10.1101/gad.1467506

Yang, 2008, The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men, Nat Rev Mol Cell Biol, 9, 206, 10.1038/nrm2346

Huang, 1999, Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes, Nat Neurosci, 2, 867, 10.1038/13165

Vega, 2004, Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis, Cell, 119, 555, 10.1016/j.cell.2004.10.024

Dequiedt, 2003, HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis, Immunity, 18, 687, 10.1016/S1074-7613(03)00109-2

Kovacs, 2005, HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor, Mol Cell, 18, 601, 10.1016/j.molcel.2005.04.021

Messaoudi, 2008, Recent advances in HSP90 inhibitors as antitumor agents, Anticancer Agents Med Chem, 8, 761, 10.2174/187152008785914824

Bali, 2005, Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors, J Biol Chem, 280, 26729, 10.1074/jbc.C500186200

Yang, 2008, Role of acetylation and extracellular location of heat shock protein 90 alpha in tumor cell invasion, Cancer Res, 68, 4833, 10.1158/0008-5472.CAN-08-0644

Kopito, 2000, Aggresomes, inclusion bodies and protein aggregation, Trends Cell Biol, 10, 524, 10.1016/S0962-8924(00)01852-3

Pandey, 2007, HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS, Nature, 447, 859, 10.1038/nature05853

Kawaguchi, 2003, The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress, Cell, 115, 727, 10.1016/S0092-8674(03)00939-5

Finkel, 2009, Recent progress in the biology and physiology of sirtuins, Nature, 460, 587, 10.1038/nature08197

He, 2001, Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia, J Clin Invest, 108, 1321, 10.1172/JCI200111537

Ropero, 2006, A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition, Nat Genet, 38, 566, 10.1038/ng1773

Ropero, 2008, Transforming pathways unleashed by a HDAC2 mutation in human cancer, Oncogene, 27, 4008, 10.1038/onc.2008.31

Choi, 2001, Expression profile of histone deacetylase 1 in gastric cancer tissues, Jpn J Cancer Res, 92, 1300, 10.1111/j.1349-7006.2001.tb02153.x

Weichert, 2008, Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis, Lancet Oncol, 9, 139, 10.1016/S1470-2045(08)70004-4

Zhu, 2004, Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis, Cancer Cell, 5, 455, 10.1016/S1535-6108(04)00114-X

Marquard, 2008, Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma, Histopathology, 53, 267, 10.1111/j.1365-2559.2008.03109.x

Weichert, 2008, Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo, Clin Cancer Res, 14, 1669, 10.1158/1078-0432.CCR-07-0990

Weichert, 2008, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy, Br J Cancer, 98, 604, 10.1038/sj.bjc.6604199

Krusche, 2005, Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis, Cancer Res Treat, 90, 15, 10.1007/s10549-004-1668-2

Bicaku, 2008, Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling, Cancer Res, 68, 1513, 10.1158/0008-5472.CAN-07-2822

Jeong, 2002, Regulation and destabilization of HIF-1 alpha by ARD1-mediated acetylation, Cell, 111, 709, 10.1016/S0092-8674(02)01085-1

Xu, 2007, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, 37, 5541, 10.1038/sj.onc.1210620

Dedes, 2009, Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities, Anticancer Drugs, 20, 321, 10.1097/CAD.0b013e3283262a32

Kelly, 2003, Phase I clinical trial of histone deacatylase inhibitor: suberoylanilide hydroxamic acid administered intravenously, Clin Cancer Res, 9, 3578

Kelly, 2005, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer, J Clin Oncol, 23, 3923, 10.1200/JCO.2005.14.167

Duvic, 2007, Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999

Olsen, 2007, Phase IIB multicenter trial of vorinostat in patients with persistent, progressive or treatment refractory cutaneous T-cell lymphoma, J Clin Oncol, 25, 3109, 10.1200/JCO.2006.10.2434

Garcia-Manero, 2008, Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes, Blood, 111, 1060, 10.1182/blood-2007-06-098061

Kirschbaum, 2009, A phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-hodgkin’s lymphoma. A California Cancer Consortium study [abstract], Haematologica, 94

Traynor, 2009, Vorinostat (NSC# 701852) in patients with relapsed non-small lung cancer: a Wisconsin Oncology Network phase II study, J Thorac Oncol, 4, 522, 10.1097/JTO.0b013e3181952478

Vansteenkiste, 2008, Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer, Invest New Drugs, 26, 483, 10.1007/s10637-008-9131-6

Woyach, 2009, Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma, J Clin Endocinol Metab, 94, 164, 10.1210/jc.2008-1631

Galanis, 2009, Phase II trial of vorinostat in recurrent gliblastoma multiforme: a north central cancer treatment group study, J Clin Oncol, 27, 2052, 10.1200/JCO.2008.19.0694

Luu, 2008, A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study, Clin Cancer Res, 14, 7138, 10.1158/1078-0432.CCR-08-0122

Blumenschein, 2008, Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanililide hydroxamic acid, SAHA) in patients with recurrent and/or metastasic head and neck cancer, Invest New Drugs, 26, 81, 10.1007/s10637-007-9075-2

Modesitt, 2008, Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 109, 182, 10.1016/j.ygyno.2008.01.009

Bradley, 2009, Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862), Cancer, 9999

Steele, 2008, A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors, Clin Cancer Res, 14, 804, 10.1158/1078-0432.CCR-07-1786

Gimsing, 2008, A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia, Eur J Haematol, 81, 170, 10.1111/j.1600-0609.2008.01102.x

Kelly, 2009, Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors, J Clin Oncol, 27, 3531, 10.1200/jco.2009.27.15_suppl.3531

Zain, 2009, Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma, J Clin Oncol, 27, 8580, 10.1200/jco.2009.27.15_suppl.8580

Giaccone, 2009, Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies, J Clin Oncol, 27, 7589, 10.1200/jco.2009.27.15_suppl.7589

Giles, 2006, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies, Clin Cancer Res, 12, 4628, 10.1158/1078-0432.CCR-06-0511

Zhang, 2008, Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat), J Clin Oncol, 26, 332, 10.1200/JCO.2007.14.7249

Sharma S, Vogelzang NJ, Beck J. Phase I pharmacokinetic and pharmacodynamic study of once-weekly i.v. panobinostat (LBH589) [abstract]. ECCO Annual Meeting Abstracts 2007

Prince, 2007, Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin’s lymphoma (abstract), J Clin Oncol, 25, 3500, 10.1200/jco.2007.25.18_suppl.3500

Duvic, 2008, Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL) (abstract), ASH Annual Meeting Abstracts, 112, 1005

Dickinson, 2009, Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma, Br J Haematol, 147, 97, 10.1111/j.1365-2141.2009.07837.x

Wolf, 2008, A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma (abstract), ASH Annual Meeting Abstracts, 112, 2781

Okamoto N, Hatake K, Yamamoto N. A phase I study of oral panobinostat (LBH589) in Japanese patients with advances solid tumors (abstract). EORTC-NCI-AACR Annual Meeting 2008

Ottmann, 2008, Phase IA/II Study of Oral Panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced heamatologic malignancies (abstract), ASH Annual Meeting Abstracts, 112, 958

Woo, 2008, Panobinostat (LBH589) pharmacokinetics (PK): implication for clinical safety and efficacy, Ann Oncol, 18, 487

de Bono, 2009, Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor, Eur J Cancer Suppl, 7, 137, 10.1016/S1359-6349(09)70467-7

Furumai, 2002, FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases, Cancer Res, 62, 4916

Sandor, 2002, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms, Clin Cancer Res, 8, 718

Marshall, 2002, A phase I trial of depsipeptide (FR901228) in patients with advanced cancer, J Exp Ther Oncol, 2, 325, 10.1046/j.1359-4117.2002.01039.x

Cabell, 2009, Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin, J Clin Oncol, 27, 19533, 10.1200/jco.2009.27.15_suppl.e19533

Shah, 2006, Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors, Clin Cancer Res, 12, 3997, 10.1158/1078-0432.CCR-05-2689

Bates, 2006, Challenges of evaluating the cardiac effects of anticancer agents, Clin Cancer Res, 12, 3871, 10.1158/1078-0432.CCR-06-1017

Molife, 2010, Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC), Ann Oncol, 21, 109, 10.1093/annonc/mdp270

Stadler, 2006, A phase II study of depsipeptide in refractory metastatic renal cell cancer, Clin Genitourin Cancer, 5, 57, 10.3816/CGC.2006.n.018

Whitehead, 2008, Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336), Invest New Drugs, 27, 469, 10.1007/s10637-008-9190-8

Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J Clin Oncol, 27, 5410, 10.1200/JCO.2008.21.6150

Piekarz, 2007, Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma, J Clin Oncol, 25, 8027, 10.1200/jco.2007.25.18_suppl.8027

Dermierre, 2009, Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL), J Clin Oncol, 27, 8546, 10.1200/jco.2009.27.15_suppl.8546

Klimek, 2008, Tolerability, pharmacodynamics and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes, Clin Cancer Res, 14, 826, 10.1158/1078-0432.CCR-07-0318

Byrd, 2005, A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia, Blood, 105, 959, 10.1182/blood-2004-05-1693

Sherman, 2009, Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma, J Clin Oncol, 27, 10.1200/jco.2009.27.15_suppl.6059

Bonfils, 2008, Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay, Clin Cancer Res, 14, 3441, 10.1158/1078-0432.CCR-07-4427

Bociek, 2008, Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL), J Clin Oncol, 20, 8507, 10.1200/jco.2008.26.15_suppl.8507

Marchion, 2005, In vivo synergy between topoisomerase II and histone deacatylase inhibitors: predictive correlates, Mol Cancer Ther, 4, 1993, 10.1158/1535-7163.MCT-05-0194

Arnold, 2007, The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer, Clin Cancer Res, 13, 18, 10.1158/1078-0432.CCR-06-0914

Hurwitz, 2008, Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors, J Clin Oncol (Meeting Abstracts), 26

Northfelt, 2009, Belinostat (Bel) down-regulates thymidylate synthase (TS) in tumor tissue: a dose-escalation study of belinostat alone and in combination with 5-fluorouracil (5-FU) (abstract), Gastrointestinal Cancers Symposium, 333

Munster, 2009, Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC, Clin Cancer Res, 15, 2488, 10.1158/1078-0432.CCR-08-1930

Kim, 2003, Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA, Cancer Res, 63, 7291

Vaishampayan, 2009, Phase IB dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC), Eur J Cancer Suppl, 7, 413, 10.1016/S1359-6349(09)71402-8

Dowdy, 2006, Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells, Mol Cancer Ther, 5, 2767, 10.1158/1535-7163.MCT-06-0209

Ramalingam, 2007, Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies, Clin Cancer Res, 13, 3605, 10.1158/1078-0432.CCR-07-0162

Owonikoko TK, Ramalingam SS, Kanterewicz B, et al. Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer 2009

Belani, 2009, Randomized, double blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small cell lung cancer (NSCLC) (abstract), Eur J Cancer Suppl, 7, 507, 10.1016/S1359-6349(09)71720-3

Ramalingam, 2010, Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer, J Clin Oncol, 28, 56, 10.1200/JCO.2009.24.9094

Rikiishi, 2007, Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid, Int J Oncol, 30, 1181

Dong, 2009, Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells, Am J Physiol Renal Physiol, 298, 293, 10.1152/ajprenal.00410.2009

Chen, 2007, Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer, J Clin Oncol, 25, 18088, 10.1200/jco.2007.25.18_suppl.18088

Teixeira, 2009, Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC), Eur J Cancer Suppl, 7, 554, 10.1016/S1359-6349(09)71876-2

Thomas, 2009, Histone deacetylase inhibitor induced modulation of anti-estrogen therapy, Cancer Lett, 280, 184, 10.1016/j.canlet.2008.12.026

Munster, 2009, Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy, J Clin Oncol, 27, 1075, 10.1200/jco.2009.27.15_suppl.1075

Reguart, 2009, Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): the TARZO trial, Eur J Cancer Suppl, 7, 550, 10.1016/S1359-6349(09)71863-4

Konduri, 2009, Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC (abstract), J Clin Oncol, 27, 14545, 10.1200/jco.2009.27.15_suppl.e14545

Bali, 2005, Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of HER2, Clin Cancer Res, 11, 6382, 10.1158/1078-0432.CCR-05-0344

Conte, 2009, Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results, J Clin Oncol, 27, 1081S, 10.1200/jco.2009.27.15_suppl.1081

Pili R, Wilky B, Salumbides B, Hammers H, Holleran JL, Egorin MJ. et al. Phase I/II trial of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with renal cell carcinoma: phase I safety and pharmacokinetic/pharmacodynamic results. In Genitourinary Cancers Symposium, Edition 2008; 371S

Nawrocki, 2006, Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells, Cancer Res, 66, 3773, 10.1158/0008-5472.CAN-05-2961

Pei, 2004, Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors, Clin Cancer Res, 10, 3839, 10.1158/1078-0432.CCR-03-0561

Weber, 2008, Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience, Blood, 112, 871, 10.1182/blood.V112.11.871.871

Badros, 2008, Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts), J Clin Oncol, 26, 8548, 10.1200/jco.2008.26.15_suppl.8548

Berenson, 2009, A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease, J Clin Oncol, 27, 19508, 10.1200/jco.2009.27.15_suppl.e19508

Rahmani, 2003, Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells, Cancer Res, 63, 8420

Insinga, 2005, Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway, Nat Med, 11, 71, 10.1038/nm1160

Frew, 2008, Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist, Proc Natl Acad Sci U S A, 105, 11317, 10.1073/pnas.0801868105

Cimino, 2006, Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia, Cancer Res, 66, 8903, 10.1158/0008-5472.CAN-05-2726

Kuendgen, 2006, The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia, Cancer, 106, 112, 10.1002/cncr.21552

Soriano, 2007, Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome, Blood, 110, 2302, 10.1182/blood-2007-03-078576

Blum, 2007, Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia, J Clin Oncol, 25, 3884, 10.1200/JCO.2006.09.4169

Juergens, 2009, Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC), J Clin Oncol, 27, 8055, 10.1200/jco.2009.27.15_suppl.8055

Dejligbjerg, 2008, Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells, Mol Cancer, 7, 70, 10.1186/1476-4598-7-70

Fantin, 2008, Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma, Cancer Res, 68, 3785, 10.1158/0008-5472.CAN-07-6091

Ellis, 2008, Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma, Clin Cancer Res, 14, 4500, 10.1158/1078-0432.CCR-07-4262

Fotheringham, 2009, Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis, Cancer Cell, 15, 57, 10.1016/j.ccr.2008.12.001

Miyanaga, 2008, Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model, Mol Cancer Ther, 7, 1923, 10.1158/1535-7163.MCT-07-2140

Doss, 2008, A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors, J Clin Oncol, 26, 2567S, 10.1200/jco.2008.26.15_suppl.2567

Sinha, 2007, A phase I/II study of the safety and anti-cancer activity of i.v. administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors, J Clin Oncol, 25, 3574, 10.1200/jco.2007.25.18_suppl.3574

Finkler, 2008, Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC), J Clin Oncol, 26, 5519, 10.1200/jco.2008.26.15_suppl.5519

Siegel, 2008, A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and i.v. bortezomib in patients with relapsed multiple myeloma, Blood, 112, 2781, 10.1182/blood.V112.11.2781.2781

Harrison, 2008, High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial, Blood, 112, 3698, 10.1182/blood.V112.11.3698.3698

Spencer, 2009, Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM), J Clin Oncol, 27, 8542, 10.1200/jco.2009.27.15_suppl.8542

Silverman, 2008, J Clin Oncol, 26, 7000, 10.1200/jco.2008.26.15_suppl.7000

Garcia-Manero, 2007, Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplatic syndrome (MDS) or acute leukemia (AML), J Clin Oncol, 25, 7062, 10.1200/jco.2007.25.18_suppl.7062

Gore, 2006, Combines methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMol and AML: clinical response, histone acetylation and DNA damage, ASH Annual Meeting Abstracts, 108, 517

Garcia-Manero, 2006, Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia, Blood, 108, 3271, 10.1182/blood-2006-03-009142

Thông tin
Thông tin xuất bản

Bulletin du Cancer

Tập 97

917-935

Thông tin tác giả